2020-03-02
Interim report for the fourth quarter 2019, 1 January – 31 December 2019 Kancera AB (publ.), org.nr. 556806-8851.
This is a translation of the report in Swedish.
Read More
2020-02-05
Kancera has received approval to start the final part of the phase Ib program for KAND567
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that it has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567. The company estimates that...
Read More
2019-12-04
Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system
Kancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows that KAND567 effectively blocks certain specific immune cells that are known to...
Read More
2019-11-26
Interim report for the third quarter 2019, 1 January – 30 September 2019
Third quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter contributed SEK 0,2 Million (0,0 Million). R&D costs for...
Read More
2019-11-25
Kancera and partner revise the patent strategy for the HDAC project
This is a translation of a press release in Swedish published in Stockholm 2019-11-22 Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors for the treatment of pain and inflammation. The companies have now decided...
Read More
2019-11-25
Kancera updates the clinical development plan for KAND567
This is a translation of a press release in Swedish published 2019-11-21 Kancera AB (Nasdaq First North Growth Market: KAN) today announces that the company intends to complete the final phase of the Phase Ib study of the drug candidate KAND567 in...
Read More
2019-09-03
Kancera unveils preclinical findings for its lead compound, KAND567, at world’s largest cardiovascular conference
Kancera AB (Nasdaq First North: KAN) announces the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to humans at the European Society of Cardiology (ESC) Congress 2019 in Paris,...
Read More
2019-08-26
Kancera develops the dosing strategy for KAND567 which means an added delay of the phase 1b study
Kancera today announces that a further developed dosing strategy is intended to be tested for the treatment with KAND567. The reason is that the modified intravenous dosing studied in the phase Ib study in August 2019 resulted in a clearly improved but...
Read More
2019-08-23
Interim report for the second quarter 2019, 1 January – 30 June 2019
Second quarter in brief 1 April – 30 June 2019 Net sales for the period (January to June) amounted to SEK 3,1 Million (0 Million) of which the second quarter contributed SEK 0 Million (0 Million). R&D costs for...
Read More
2019-08-19
Kancera provides an operational update and announces an issue of shares in accordance with the agreement with Global Corporate Finance
Kancera AB (Nasdaq First North: KAN) announces that the company's clinical Phase Ib study according to plan will start again today. The aim is to report the study in November 2019. Kancera also announces new financing through a third new issue of...
Read More